Fig. 4
Suppression of FTO resensitizes resistant cells to Ara-C in vitro and in vivo. A Comparison of FTO mRNA expression in BM samples from AML patient with high versus poor response to Ara-C (GSE97393). B, C CCK-8 assays for SKNO-1 and Kasumi-1 cells transfected with wild-type FTO (wt-FTO), mutant FTO (mut-FTO) or mock vectors (B); or FTO shRNA or scramble vectors (C) treated with varying concentrations of Ara-C for 48 h. D CCK-8 assays for SKNO-1 and Kasumi-1 cells treated with 10 µM FB23-2 for 6 h followed by co-treatment of different concentrations of Ara-c for 48 h. E CCK-8 assays for primary BM cells collected from a relapsed t(8;21) AML patients with 10 µM FB23-2 treatment for 6 h followed by co-treatment of different concentrations of Ara-c for 48 h. F The external view of nude mice bearing SKNO-1 cell xenografts (n = 6 for each group) treated with DMSO, Ara-C, FB23-2, or a combination of Ara-C and FB23-2. G, H The growth curve of tumor volume (G) and the final tumor weight (H) for each group as indicated in F. I–L NOD/SCID/IL2rγnull immunodeficient NSG mice injected with SKNO-1 cells through tail vein treated with DMSO, Ara-C, FB23-2, or a combination of Ara-C and FB23-2 (n = 6 for each group). I Blast cells percentage in bone marrow (BM), J Wright-Giemsa staining of bone marrow and H&E staining of livers and spleens, K spleen weights and L representative external views of the spleens were shown